Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000231790.8(MLH1):c.887T>G(p.Leu296Ter) variant causes a stop gained, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. L296L) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 3-37020312-T-G is Pathogenic according to our data. Variant chr3-37020312-T-G is described in ClinVar as [Pathogenic]. Clinvar id is 90430.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr3-37020312-T-G is described in Lovd as [Pathogenic].
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter
clinical testing
Myriad Genetics, Inc.
Jul 18, 2023
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
Lynch syndrome Pathogenic:1
Pathogenic, reviewed by expert panel
research
International Society for Gastrointestinal Hereditary Tumours (InSiGHT)
Sep 05, 2013
Coding sequence variation resulting in a stop codon -
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter
clinical testing
GeneDx
Oct 11, 2016
This variant is denoted MLH1 c.887T>G at the cDNA level and p.Leu296Ter (L296X) at the protein level. The substitution creates a nonsense variant, which changes a Leucine to a premature stop codon (TTA>TGA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. The International Society for Gastrointestinal Hereditary Tumours Incorporated (InSiGHT) classifies this variant as pathogenic (Thompson 2014). MLH1 Leu296Ter has been reported in at least one individual with Lynch syndrome (Lee 2005). We consider this variant to be pathogenic. -
For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in MLH1 are known to be pathogenic (PMID: 15713769, 24362816). This variant has been observed in individuals affected with Lynch syndrome and colorectal cancer (PMID: 15996210, 28445943). ClinVar contains an entry for this variant (Variation ID: 90430). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Leu296*) in the MLH1 gene. It is expected to result in an absent or disrupted protein product. -
The p.L296* pathogenic mutation (also known as c.887T>G), located in coding exon 11 of the MLH1 gene, results from a T to G substitution at nucleotide position 887. This changes the amino acid from a leucine to a stop codon within coding exon 11. This mutation has been reported in multiple individuals who meet Amsterdam II criteria and/or have mismatch repair deficient colorectal cancer (Zhang J et al. Oncotarget, 2017 Apr;8:24533-24547; Yang M et al. Ther Adv Med Oncol, 2021 Jun;13:17588359211023290; Jiang W et al. Int J Cancer, 2019 May;144:2161-2168; Lee SC et al. Clin Genet, 2005 Aug;68:137-45). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -